Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
2
Neutral
8
Bullish
4
Bearish
18
Neutral
8
Bullish
20
Bearish
16
Neutral
0
Bullish
16
Discovery themes featuring this stock
Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen.
In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage.
The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance.
Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway.
The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
13,432 Cr
High Risk
26.2
28.0
1.3
3.4
627.45
412.05
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
952.80 | 17,066 Cr | 10.96 | 1.97 | 0.63 | 17.79 | 21.15 | 14.81 | |
553.50 | 13,432 Cr | 25.15 | 3.37 | 0.27 | 12.88 | 13.37 | 7.86 | |
1223.60 | 12,608 Cr | 41.14 | 6.90 | 0.73 | 17.73 | 23.48 | 15.38 | |
298.00 | 11,389 Cr | 57.11 | 3.01 | 0.00 | 10.47 | 11.28 | 4.65 | |
908.70 | 11,164 Cr | 20.54 | 3.70 | 0.55 | 17.59 | 23.34 | 14.94 | |
1550.00 | 9,420 Cr | 63.45 | 14.28 | 0.47 | 26.53 | 33.34 | 17.54 | |
201.50 | 8,791 Cr | 115.90 | 10.39 | 0.00 | 15.22 | 18.17 | 8.65 |
Granules India Ltd (GRANULES) is currently trading at 575.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Granules India Limited is a vertically integrated pharmaceutical company specializing in Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). Known for its leadership in off-patent drugs, it serves global branded and generic pharma firms with core products like Paracetamol and Ibuprofen. In Q3 FY26, Granules India reported a 22% year-over-year revenue growth, driven mainly by the Finished Dosage segment in North America and Europe. Their EBITDA also saw a meaningful jump of 34% year-over-year, signifying improved operating leverage. The company's strategic expansions include significant market penetration in Europe achieving a 131% year-over-year revenue growth in the region. They hold a leading position in 25% of their US product portfolio and received key GMP certifications, bolstering their regulatory compliance. Granules India is actively engaged in R&D, noted for their strides in peptide chemistry and controlled substances. They have made advances like the tentative approval of Amphetamine ER in the US market, asserting their innovative pathway. The management expressed confidence in resolving FDA concerns at their Gagillapur site. Concurrently, they are expanding geographical reach and strategic areas like peptides, complex generics, and sustainability efforts, maintaining robust governance and supply chain resilience.
Over the past 52 weeks, Granules India Ltd has traded between a low of ₹412.05 and a high of ₹627.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Granules India Ltd has a market capitalization of approximately 13,431.71. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Granules India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 26.17 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 13,431.71 Cr, Granules India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Granules India Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Granules India Ltd is 26.17. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The 10,000 crore Biopharma Shakti initiative supports domestic production of biologics and biosimilars, aligning with Granules India's strategic shift toward complex generics and its peptide CDMO platform.
Granules India's board has approved a plan to raise up to ₹1,762.50 crore. This includes ₹1,462.50 crore from convertible warrants and ₹300 crore from the issuance of equity shares.
Press Release
Granules India announced its US packaging subsidiary’s Manassas, VA facility received an FDA Establishment Inspection Report with No Action Indicated after a Dec 1–3, 2025 inspection, marking a second zero-observation audit.
Press Release
Granules Consumer Health LLC's Manassas, VA packaging facility received an FDA Establishment Inspection Report with No Action Indicated after a Dec 1–3, 2025 inspection, marking a second zero-observation audit (prior: Mar 2023).
